704 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
ABBV AbbVie Inc. $95.37 $144.42B N/A
Article Searches
Top Research Reports for Intel, AbbVie & United Technologies http://www.zacks.com/research-daily/217961/top-research-reports-for-intel-abbvie-united-technologies?cid=CS-ZC-FT-217961 Mar 04, 2019 - Top Research Reports for Intel, AbbVie & United Technologies
AbbVie Gets CHMP Nod for Psoriasis Candidate Risankizumab http://www.zacks.com/stock/news/357598/abbvie-gets-chmp-nod-for-psoriasis-candidate-risankizumab?cid=CS-ZC-FT-357598 Mar 04, 2019 - AbbVie (ABBV) gets positive opinion of the CHMP recommending marketing approval for risankizumab for the treatment of moderate-to-severe plaque psoriasis.
Big Pharma's Showdown With Congress Over Drug Pricing: What It Really Means for You https://www.fool.com/investing/2019/02/27/big-pharmas-showdown-with-congress-over-drug-prici.aspx?source=iedfolrf0000001 Feb 27, 2019 - A Senate committee roasted top executives of the biggest drugmakers. But will anything change for ordinary Americans?
Congress Grills Drugmakers: 5 Key Takeaways https://www.fool.com/investing/2019/02/26/congress-grills-drugmakers-5-key-takeaways.aspx?source=iedfolrf0000001 Feb 26, 2019 - Top drug companies addressed sky-high drug prices on Capitol Hill today.
Momenta (MNTA) Q4 Loss Narrower Than Expected, Revenues Beat http://www.zacks.com/stock/news/356858/momenta-mnta-q4-loss-narrower-than-expected-revenues-beat?cid=CS-ZC-FT-356858 Feb 25, 2019 - Momenta (MNTA) reported a narrower loss in Q4, while sales came ahead of expectations.
Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates http://www.zacks.com/stock/news/356445/pharma-stock-roundup-mrk-buys-imdz-fda-grants-priority-review-to-some-candidates?cid=CS-ZC-FT-356445 Feb 22, 2019 - Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).
Roche's (RHHBY) BLA for Lymphoma Drug Gets Priority Review http://www.zacks.com/stock/news/355489/roches-rhhby-bla-for-lymphoma-drug-gets-priority-review?cid=CS-ZC-FT-355489 Feb 19, 2019 - The FDA accepts Roche's (RHHBY) BLA for polatuzumab vedotin and NDAs for entrectinib, and grants Priority Review status to the applications.
These 3 Value Stocks Are Absurdly Cheap Right Now https://www.fool.com/investing/2019/02/16/these-3-value-stocks-are-absurdly-cheap-right-now.aspx?source=iedfolrf0000001 Feb 16, 2019 - Twitter, ExxonMobil, and Abbvie are companies you need to look at today.
AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma http://www.zacks.com/stock/news/353842/abbvie-buys-rights-to-novel-immunotherapy-for-multiple-myeloma?cid=CS-ZC-FT-353842 Feb 12, 2019 - AbbVie (ABBV) enters a global strategic transaction agreement with privately-held Teneobio to develop and commercialize the latter's pre-clinical immunotherapy candidate, TNB-383B, as a multiple myeloma treatment.
Here's Why Coherus BioSciences Rose 48.7% in January https://www.fool.com/investing/2019/02/11/heres-why-coherus-biosciences-rose-487-in-january.aspx?source=iedfolrf0000001 Feb 11, 2019 - The company secured a deal paving the way to commercialize a generic version of the former best-selling drug in the world.

Pages: 1234567891011...71

<<<Page 6>